CLINICAL_TRIALS
trial_result
· 2023-05-01
Clinical Trial Update: Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis [Phase 2]
Summary
Phase 2 trial update on safety and efficacy of CD5024 0.3% Cream in adults with atopic dermatitis; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Galderma R&D | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2023-05-01